{"success":true,"data":{"pressRelease":{"id":"35170","rtpr_id":"nGNX3YMbyP","ticker":"PLYX","exchange":"NASDAQ","all_tickers":["PLYX"],"title":"Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards","author":"Globe Newswire","published_at":"2026-05-14T13:15:00.123Z","article_body":"PARAMUS, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq:\nPLYX), a clinical-stage biotechnology company focused on developing\ndisease-modifying therapies for rare, pediatric lysosomal storage disorders\n(LSDs), announces that it has been named a double winner of the 2026 GHP\nMagazine Healthcare & Pharmaceutical Awards as both the Best Pediatric\nLysosomal Storage Disease Therapeutics 2026 - USA and the Rare\nNeurodegenerative Disease Drug Development Excellence Award 2026 - USA awards\nrecipient.\n\n“While current treatments have pushed care forward for lysosomal storage\ndisorders, children and their families still face a significant daily\ntreatment burden,” said Alex Yang, J.D., LL.M., Chief Executive Officer of\nPolaryx Therapeutics. “This recognition is a good reminder of the importance\nof our mission to address these critical unmet needs by delivering effective,\npatient-centered solutions that improve the overall care experience.”\n\nFollowing a thorough, merit-led evaluation process by GHP’s expert research\nteam, Polaryx Therapeutics has been recognized as an R&D leader in\ntherapeutics for rare diseases like rare lysosomal storage disorders. The\njudging panel selected Polaryx based on its outstanding innovation, market\nimpact, business performance, and vital contributions to patient outcomes.\n\nThe 2026 Healthcare & Pharmaceutical Awards honor the visionaries reshaping\nmodern medicine. Launched by GHP Magazine in 2015, the awards celebrate the\nlife-changing treatments, patient-centered services, and community health\ninitiatives that rise to meet today's complex challenges and set new standards\nfor industry excellence.\n\nPolaryx’s lead program, PLX-200, is an oral small molecule designed to\ntarget multiple underlying disease mechanisms across several LSDs and is being\nadvanced through the SOTERIA Phase 2 basket trial evaluating multiple\nindications and expected to launch in the second half of 2026.  \n\nAbout Global Health & Pharma Magazine\n\nGlobal Health & Pharma Magazine is part of AI Global Media, an internationally\nfocused B2B digital publishing group founded in 2010. The group is committed\nto delivering trustworthy content to every one of its readers, subscribers,\nclients, contributors, advertisers and visitors. Global Health & Pharma\nMagazine is a quarterly digital publication dedicated to the Healthcare,\nPharmaceutical and Life Science industries. Each quarter Global Health &\nPharma Magazine brings to its readers the need-to-know news and updates from\nkey sectors and magnify the work of those that are setting the pace and\nlooking to change their respective sectors for the better. Utilizing this\nreach, we aim to provide support and help showcase the latest developments,\nmost promising innovations and leading companies across the medical and health\nindustries.\n\nAbout Polaryx Therapeutics\n\nPolaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused\non developing patient-friendly small molecule and gene therapy treatments for\nrare orphan lysosomal storage disorders (LSDs). Founded in 2014, Polaryx seeks\nto deliver safe, effective, and patient-friendly treatments that address the\nunderlying pathophysiology of these catastrophic diseases and their\nsignificant unmet need. Our approach integrates small molecule therapies,\nincluding a combination therapy, and a gene therapy, positioning us to\npotentially address both the genetic and downstream pathological features of\nLSDs. Our small molecule drug candidates share similar modes of action that\nhave been demonstrated to address lysosomal dysfunction, neuroinflammation,\nand neuronal loss in our validated animal models that closely mimic human\nclinical phenotypes. Our most advanced product candidate, PLX-200, targets\nseveral LSDs and we intend to launch SOTERIA, a Phase 2 basket trial, to\nevaluate PLX-200’s safety and efficacy. For more information, please visit\nwww.polaryx.com.\n\nForward-Looking Statements\n\nCertain statements in this press release may constitute “forward-looking\nstatements” within the meaning of the federal securities laws, including,\nbut not limited to, statements regarding: Polaryx’s clinical development\nplans for PLX-200, including the timing for initiation of the SOTERIA trial.\nWords such as “may,” “might,” “will,” “objective,”\n“intend,” “should,” “could,” “can,” “would,” “expect,”\n“believe,” “design,” “estimate,” “predict,” “potential,”\n“develop,” “plan” or the negative of these terms, and similar\nexpressions, or statements regarding intent, belief, or current expectations,\nare forward-looking statements. While Polaryx believes these forward-looking\nstatements are reasonable, undue reliance should not be placed on any such\nforward-looking statements, which are based on information available to the\ncompany on the date of this release. These forward-looking statements are\nbased upon current estimates and assumptions and are subject to various risks\nand uncertainties (including, without limitation, those set forth in\nPolaryx’s filings with the U.S. Securities and Exchange Commission (the\nSEC), many of which are beyond the company’s control and subject to change.\nActual results could be materially different. Risks and uncertainties include:\nglobal macroeconomic conditions and related volatility, expectations regarding\nthe initiation, progress, and expected results of Polaryx’s clinical trials;\nexpectations regarding the timing, completion and outcome of Polaryx’s\nclinical trials; the timing or likelihood of regulatory filings and approvals;\nliquidity and capital resources; and other risks and uncertainties identified\nin Polaryx’s most recently filed Form 10-K with the SEC and subsequent\ndisclosure documents Polaryx may file with the SEC. Polaryx claims the\nprotection of the Safe Harbor contained in the Private Securities Litigation\nReform Act of 1995 for forward-looking statements. Polaryx expressly disclaims\nany obligation to update or alter any statements whether as a result of new\ninformation, future events or otherwise, except as required by law.\n\nMedia Contact:\n\nCORE IR\n(212) 655-0924\nmedia@polaryx.com\n\nInvestor Contact:\n\nCORE IR\n(212) 655-0924\ninvestor@polaryx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/64e2f507-40e8-46aa-b22e-6661e7035467)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3YMbyP","title":"Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards","author":"Globe Newswire","ticker":"PLYX","created":"2026-05-14T13:15:00.123Z","tickers":["PLYX"],"exchange":"NASDAQ","article_body":"PARAMUS, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq:\nPLYX), a clinical-stage biotechnology company focused on developing\ndisease-modifying therapies for rare, pediatric lysosomal storage disorders\n(LSDs), announces that it has been named a double winner of the 2026 GHP\nMagazine Healthcare & Pharmaceutical Awards as both the Best Pediatric\nLysosomal Storage Disease Therapeutics 2026 - USA and the Rare\nNeurodegenerative Disease Drug Development Excellence Award 2026 - USA awards\nrecipient.\n\n“While current treatments have pushed care forward for lysosomal storage\ndisorders, children and their families still face a significant daily\ntreatment burden,” said Alex Yang, J.D., LL.M., Chief Executive Officer of\nPolaryx Therapeutics. “This recognition is a good reminder of the importance\nof our mission to address these critical unmet needs by delivering effective,\npatient-centered solutions that improve the overall care experience.”\n\nFollowing a thorough, merit-led evaluation process by GHP’s expert research\nteam, Polaryx Therapeutics has been recognized as an R&D leader in\ntherapeutics for rare diseases like rare lysosomal storage disorders. The\njudging panel selected Polaryx based on its outstanding innovation, market\nimpact, business performance, and vital contributions to patient outcomes.\n\nThe 2026 Healthcare & Pharmaceutical Awards honor the visionaries reshaping\nmodern medicine. Launched by GHP Magazine in 2015, the awards celebrate the\nlife-changing treatments, patient-centered services, and community health\ninitiatives that rise to meet today's complex challenges and set new standards\nfor industry excellence.\n\nPolaryx’s lead program, PLX-200, is an oral small molecule designed to\ntarget multiple underlying disease mechanisms across several LSDs and is being\nadvanced through the SOTERIA Phase 2 basket trial evaluating multiple\nindications and expected to launch in the second half of 2026.  \n\nAbout Global Health & Pharma Magazine\n\nGlobal Health & Pharma Magazine is part of AI Global Media, an internationally\nfocused B2B digital publishing group founded in 2010. The group is committed\nto delivering trustworthy content to every one of its readers, subscribers,\nclients, contributors, advertisers and visitors. Global Health & Pharma\nMagazine is a quarterly digital publication dedicated to the Healthcare,\nPharmaceutical and Life Science industries. Each quarter Global Health &\nPharma Magazine brings to its readers the need-to-know news and updates from\nkey sectors and magnify the work of those that are setting the pace and\nlooking to change their respective sectors for the better. Utilizing this\nreach, we aim to provide support and help showcase the latest developments,\nmost promising innovations and leading companies across the medical and health\nindustries.\n\nAbout Polaryx Therapeutics\n\nPolaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused\non developing patient-friendly small molecule and gene therapy treatments for\nrare orphan lysosomal storage disorders (LSDs). Founded in 2014, Polaryx seeks\nto deliver safe, effective, and patient-friendly treatments that address the\nunderlying pathophysiology of these catastrophic diseases and their\nsignificant unmet need. Our approach integrates small molecule therapies,\nincluding a combination therapy, and a gene therapy, positioning us to\npotentially address both the genetic and downstream pathological features of\nLSDs. Our small molecule drug candidates share similar modes of action that\nhave been demonstrated to address lysosomal dysfunction, neuroinflammation,\nand neuronal loss in our validated animal models that closely mimic human\nclinical phenotypes. Our most advanced product candidate, PLX-200, targets\nseveral LSDs and we intend to launch SOTERIA, a Phase 2 basket trial, to\nevaluate PLX-200’s safety and efficacy. For more information, please visit\nwww.polaryx.com.\n\nForward-Looking Statements\n\nCertain statements in this press release may constitute “forward-looking\nstatements” within the meaning of the federal securities laws, including,\nbut not limited to, statements regarding: Polaryx’s clinical development\nplans for PLX-200, including the timing for initiation of the SOTERIA trial.\nWords such as “may,” “might,” “will,” “objective,”\n“intend,” “should,” “could,” “can,” “would,” “expect,”\n“believe,” “design,” “estimate,” “predict,” “potential,”\n“develop,” “plan” or the negative of these terms, and similar\nexpressions, or statements regarding intent, belief, or current expectations,\nare forward-looking statements. While Polaryx believes these forward-looking\nstatements are reasonable, undue reliance should not be placed on any such\nforward-looking statements, which are based on information available to the\ncompany on the date of this release. These forward-looking statements are\nbased upon current estimates and assumptions and are subject to various risks\nand uncertainties (including, without limitation, those set forth in\nPolaryx’s filings with the U.S. Securities and Exchange Commission (the\nSEC), many of which are beyond the company’s control and subject to change.\nActual results could be materially different. Risks and uncertainties include:\nglobal macroeconomic conditions and related volatility, expectations regarding\nthe initiation, progress, and expected results of Polaryx’s clinical trials;\nexpectations regarding the timing, completion and outcome of Polaryx’s\nclinical trials; the timing or likelihood of regulatory filings and approvals;\nliquidity and capital resources; and other risks and uncertainties identified\nin Polaryx’s most recently filed Form 10-K with the SEC and subsequent\ndisclosure documents Polaryx may file with the SEC. Polaryx claims the\nprotection of the Safe Harbor contained in the Private Securities Litigation\nReform Act of 1995 for forward-looking statements. Polaryx expressly disclaims\nany obligation to update or alter any statements whether as a result of new\ninformation, future events or otherwise, except as required by law.\n\nMedia Contact:\n\nCORE IR\n(212) 655-0924\nmedia@polaryx.com\n\nInvestor Contact:\n\nCORE IR\n(212) 655-0924\ninvestor@polaryx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/64e2f507-40e8-46aa-b22e-6661e7035467)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-14T13:15:00.178093617Z","server_sent_at_ms":1778764500178},"received_at":"2026-05-14T13:15:00.237Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}